依米康 reported revenue of ¥0.92B for the period ended 2026-06-30, +24.7% year on year. Net income was ¥0.02B, a 2.3% net margin on a 16.1% gross margin. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.92B | +24.7% |
| Gross profit | ¥0.15B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.02B | +41.1% |
| Gross margin | 16.1% | Net margin 2.3% |
| Revenue Q/Q | +20.2% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.77B | 83.9% |
| R&D | ¥0.03B | 3.2% |
| SG&A | ¥0.06B | 6.2% |
| Tax & other | ¥-0.01B | -0.7% |
| Item | Amount |
|---|---|
| Total assets | ¥2.55B |
| Total liabilities | ¥1.89B |
| Shareholders' equity | ¥0.66B |
| Equity / assets | 25.8% |
| Operating cash flow | ¥-0.04B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | -766% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
初灵信息 ・ 金信诺 ・ 卫宁健康 ・ 仟源医药 ・ 常山药业 ・ 星星科技 ・ 开山股份 ・ 精锻科技 ・ 新天科技 ・ 新莱应材 ・ 雅本化学 ・ 隆华科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies